Throughout, we've cited only peer-reviewed studies, and we're careful to distinguish what's proven in humans from what's still emerging from the lab
doi:10.1007/s13300-020-00917-8 268
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
These barriers drive millions of people toward alternatives, even unproven ones
How do GLP-1 and Peptide YY differ in their functions
Because of the potential link between GLP-1 drugs and thyroid cancer, those with MEN 2 should avoid these medications